Gene transfer as an approach to treating hemophilia

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue 1, 2003, Pages 107-119

  High, Katherine A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

AAV; Adenovirus; Gene therapy; Hemophilia A; Hemophilia B; Retrovirus

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTEIN; RETROVIRUS VECTOR;

CLINICAL TRIAL; COMORBIDITY; GENE DELIVERY SYSTEM; GENE TRANSFER; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MOLECULE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS; FACTOR IX; FACTOR VIII; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; PROTEIN STRUCTURE, TERTIARY; RETROVIRIDAE; TRANSFECTION;

EID: 0037325357     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37945     Document Type: Review

References (110)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basille G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000;288:669-672
2. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-2413
3. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotype correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002;99: 2670-2676
4. Xu L, Sands MS, Gao C, Ponder KP. Retroviral vector-mediated expression of therapeutic levels of canine factor IX in adult and neonatal mice. Mol Ther 2002;5:S157 (Abst)
5. Couto L, Jian H, Scallan C, et al. Hemophilia A gene therapy in mouse and dog models using an AAV-FVIII vector. Mol Ther 2002;5:S84 (Abst)
6. Kyrle PA, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000;34:457-462
7. van Kylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-3682
8. Kundu RK, Sangiorgi F, Wu LY, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998;92:168-174
9. Bi L, Lawler AM, Antonarakis SE, et al. Targeted disruption of the mouse factor VIII gene: A model for hemophilia A. Nat Genet 1995;10:119-121
10. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997;90:3962-3966
11. Wang L, Zoppe M, Hackeng TM, et al. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci USA 1997;94:11563-11566
12. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 1989; 86:10095-10099
13. Mauser AE, Whitney KM, Lothrop CD Jr. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood 1996; 88:3451-3455
14. Evans JP, Watzke HH, Ware JL, Stafford DW, High KA. Molecular cloning of a cDNA encoding canine factor IX. Blood 1989;74:207-212
15. Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost 1998;79: 317-322
16. Wu SM, Stafford DW, Ware JL. Deduced amino acid sequence of mouse blood-coagulation factor IX. Gene 1990;86: 275-278
17. MASAC Recommendation #120: MASAC Recommendations for Conducting Gene Therapy Clinical Trials in Persons with Bleeding Disorders. New York: National Hemophilia Foundation; 2002. (On-line) Available: www.hemophilia.org/programs/masac/masac/masac120htm
18. Green PM, Montandon AJ, Bentley DR, Giannelli F. Genetics and molecular biology of haemophilias A and B. Blood Coagul Fibrinolysis 1991;2:539-565
19. Pastore L, Morral N, Zhou H, et al. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 1999;10:1773-1781
20. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther 2001;4:192-199
21. Nathwani AC, Davidoff A, Hanawa H, et al. Factors influencing in-vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA. Blood 2001;97:1258-1265
22. Ge Y, Powell S, Van Roey M, McArthur JG. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX. Blood 2001;97:3733-3737
23. Nathwani AC, Davidoff AM, Hanawa H, et al. Sustained high level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002;100: 1662-1669
24. Ahmed MM, Multimer DJ, Elias E, et al. A combined management protocol for patients with coagulation disorders infected with hepatitis C virus. Br J Haematol 1996;95:383-388
25. Aledort LP, Levine PH, Hilgartner M, et al. A study of liver biopsies and liver disease among hemophiliacs. Blood 1985; 66:367-372
26. Hanley JP, Jarvis LM, Andrews J, et al. Investigation of chronic hepatitis C infection in individuals with haemophilia: assessment of invasive and non-invasive methods. Br J Haematol 1996;94:159-165
27. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993;262:117-119
28. Bosch A, McCray PB, Chang SMW, et al. Proliferation induced by keratinocyte growth factor enhances in vivo retroviral-mediated gene transfer to mouse hepatocytes. J Clin Invest 1996;98:2683-2687
29. Xu L, Haskins ME, Melniczek JR, et al. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther 2002;5:141-153
30. van den Driessche T, Vanslembrouck V, Goovaerts I, et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci USA 1999;96:10379-10384
31. Bowling WM, Kennedy SC, Cai SR, et al. Portal branch occlusion safely facilitates in vivo retroviral vector transduction of rat liver. Hum Gene Ther 1996;10:2113-2121
32. McCormack JE, Edwards W, Sensintaffer J, et al. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. Mol Ther 2001;3:516-525
33. Powell JS, Ragni MV, White GC, et al. Results from one year follow up of a phase I trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2001;98: 693a (Abst)
34. Greengard JS, Jolly DJ. Animal testing of retroviral-mediated gene therapy for factor VIII deficiency. Thromb Haemost 1999;82:555-561
35. Cai S-R, Kennedy SC, Bowling WM, Flye MW, Ponder KP. Therapeutic levels of human protein C in rats after retroviral vector-mediated hepatic gene therapy. J Clin Invest 1998;101: 2831-2841
36. Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee. Minutes of Meeting. Bethesda, Maryland; March 11-12, 1999. (On-line) Available: www4.od.nih.gov/oba/rac/minutes/3-99RAC.htm
37. Biological Response Modifiers Advisory Committee. Twenty-eighth Meeting. Bethesda, Maryland; 2000. (On-line) Available: www.fda.gov/ohrms/dockets/ac/cber00.htm
38. Frankel M, Chapman A. Human inheritable genetic modificatons: assessing scientific, ethical, religious and policy issues. 2000 (On-line). Available: http://www.aaas.org/spp/dspp/sfrl/germline/main.htm
39. Roehl HH, Leibbrandt ME, Greengard JS, et al. Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene; no evidence of germ line transduction. Hum Gene Ther 2000;11:2529-2540
40. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996;70:8098-8108
41. Kessler PD, Podsakoff GM, Chen X, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996;93:14082-14087
42. Herzog R, Hagstrom N, Kung S, et al. Stable gene transfer and expression of human FIX following intramuscular injection of recombinant AAV. Proc Natl Acad Sci USA 1997;94: 5804-5809
43. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997;16:270-276
44. Herzog R, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med 1999;5:56-63
45. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med 1999;5:64-70
46. Wagner JA, Moran ML, Messner AH, et al. A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis. Hum Gene Ther 1998;9: 889-909
47. Wagner JA, Reynolds T, Moran ML, et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 1998;351:1702-1703
48. Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001;4:586-592
49. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000;24:257-261
50. Carmen IH. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 2001;3:425-428
51. Schneli MA, Zhang Y, Tazelaar J, et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol Ther 2001;3:708-722
52. Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee. Minutes of Meeting. Bethesda, Maryland; December 8-10, 1999. (Online) Available: www4.od.nih.gov/oba/rac/minutes/1299rac.pdf
53. Manno CS, Chew A, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;(in press)
54. Arruda VR, Couto L, Leonard D, et al. Risk of inadvertent germline transmission of vector DNA following intravascular delivery of recombinant AAV vector. Mol Ther 2002;5:S159 (Abst)
55. Arruda VR, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001;97:130-138
56. Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther 2002;13:1281-1291
57. Greelish JP, Su LT, Lankford EB, et al. Stable restoration of the sarcogylcan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated adeno-associated viral vector. Nat Med 1999;5:439-443
58. Arruda VR, Stedman H, Nichols TC, et al. Sustained correction of hemophilia B phenotype following intravascular delivery of AAV vector to skeletal muscle. Mol Ther 2002;5:S157 (Abst)
59. Xiao W, Chirmule N, Berta SC, et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999;73: 3994-4003
60. Chao H, Liu Y, Rabinowitz J, et al. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther 2000;2:619-623
61. Heartlein MW, Roman VA, Jiang J-L. Long-term production and delivery of human growth hormone in vivo. Proc Natl Acad Sci USA 1994;91:10967-10971
62. Selden RF, Skoskiewicz MJ, Howie KB, Russell PS, Goodman HM. Implantation of genetically engineered fibroblasts into mice: implications for gene therapy. Science 1987;236: 714-718
63. Roth DA, Tawa NE, O'Brien JM, Treco DA, Selden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001;344:1735-1742
64. Wolff G, Worgall S, Van RN, et al. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletioh of tissue macrophages in the target organ. J Virol 1997;71:624-629
65. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8:37-44
66. Zhang Y, Chirmule N, Gao G-P, et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001;3:697-707
67. Yang YP, Ertl HCJ, Wilson JM. MHC class I-restricted cytotoxic T-lymphocytes to viral-antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994;1:433-442
68. Yang YP, Xiang ZQ, Ertl HCJ, Wilson JM. Up-regulation of class-I major histocompatibility complex antigens by interferon-gamma is necessary for T-cell mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 1995;92:7257-7261
69. Yang YP, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC dass I-restricted CD4(+) CTLS in-vivo. J Immunol 1995;155:2564-2570
70. Kafri T, Morgan D, Krahl T, et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998;95:11377-11382
71. Kay MA, Landen CN, Rothenberg SR, et al. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994;91:2353-2357
72. Lozier JN, Metzger ME, Donahue RE, Morgan RA. Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity. Blood 1999;94:3968-3975
73. Lozier JN, Csako G, Mondoro TH, et al. Toxicity of a first-generation of adenoviral vector in macaques. Hum Gene Ther 2002;12:113-124
74. Gallo-Penn AM, Shirley PS, Andrews JL, et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001;86:107-113
75. Parks RJ, Chen L, Anton M, et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996;93:13565-13570
76. Chen H-H, Mack LM, Kelly R, et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997;94:1645-1650
77. Morsy MA, Gu M, Motzel S, et al. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998;95:7866-7871
78. Morral N, Parks RJ, Zhou H, et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of α1-antitrypsin with negligible toxicity. Hum Gene Ther 1998;9:2709-2716
79. Mortal N, O'Neil W, Zhou H, Langston C, Beaudet A. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wildtype and E2a deleted vectors. Hum Gene Ther 1997;8:1275-1286
80. Schiedner G, Morrall N, Parks RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18:180-183
81. Balagué C, Zhou J, Dai Y, et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000;95:820-828
82. Maione D, Wiznerowicz M, Delmastro P, et al. Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum Gene Ther 2000;11:859-868
83. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci USA 2001;98:13282-13287
84. Oka K, Pastore L, Kim I-H, et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001;103:1274-1281
85. Bristol JA, Shirley P, Idamakanti N, Kaleko M, Connelly S. In vivo dose threshold effect of adenoviral-mediated factor VIII cone therapy in hemophiliac mice. Mol Ther 2000;2: 223-232
86. Tao N, Gao G-P, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001;3:28-35
87. Fang X, Zhang W-W, Sobol RE, et al. Studies in non-human primate and hemophilic dog models of a "gutless" adenovirus vector for treatment of hemophilia A. Blood 2000;96:428a (Abst)
88. Brown BD, Shi GX, Grant F, et al. Preclinical trials of a helper-dependent adenoviral vector for the treatment of murine and canine models of hemophilia A. Mol Ther 2002; 5:S82 (Abst)
89. A phase I single-dose, dose-escalation study of MiniAdFVIII vector in patients with severe hemophilia A. Bethesda, MD: National Institutes of Health, Office of Biotechnology Activities; 2002. (On-line) Available: www4.od.nih.gov/oba/rac/trialqueryform.asp
90. Fang X, Andreason G, Hariharan M, et al. Pre-clinical efficacy and safety studies of a gutless adenovirus vector (MaxADFVIII) for treatment of hemophilia A. Presented at the XVIII ISTH Meeting. Paris, France, 2001, Abstract #OC2490
91. Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee. Minutes of Meeting. Bethesda, MD: National Institutes of Health; 2000. (On-line) Available: www4.od.nih.gov/oba/rac/minutes/Sept00RACMin.pdf
92. A phase I safety study in patients with severe hemophilia B (factor IX deficiency) using adeno-associated viral vector to deliver the gene for human factor IX into the liver. Bethesda, MD: National Institutes of Health, Office of Biotechnology Activities; 2002. (On-line) Available: www4.od.nih.gov/oba/rac/trialqueryform.asp
93. Nakai H, Ohashi K, Arruda V, et al. A proposed rAAV-liver directed clinical trial for hemophilia B. Blood 2000;96:798a (Abst)
94. Group FMCS. Interobserver and intraobserver variation in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20
95. Bedossa P, Poynard T, Group MCS. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24:289-293
96. Boyce N. Trial halted after gene shows up in semen. Nature 2001;414:677
97. Summerford C, Samulski RJ. Membrane-associated heparan sulphate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998;72:1438-1445
98. Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee. Minutes of Meeting. Bethesda, MD: National Institutes of Health; 2001. (On-line) Available: www4.od.nih.gov/oba
99. Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee. Minutes of Meeting. Bethesda, MD: National Institutes of Health; 2002. (On-line) Available: www4.od.nih.gov/oba
100. Biological Response Modifiers Advisory Committee. Issues Pertaining To Inadvertent Germline Transmission Of Gene Transfer Vectors. Gaithersburg, MD: FDA; 2002. (On-line) Available: www.fda.gov/ohrms/dockets/ac/02/briefing/3855B2_01.doc
101. Schuettrumpf J, Liu Y-L, Herzog RW, High KA, Arruda VR. Effects of anticoagulant drugs on in vivo AAV mediated liver-directed gene transfer. Mol Ther 2002;5:S40 (Abst)
102. Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001;8:1343-1346
103. Department of Health and Human Services, National Institutes of Health Recombinant DNA Advisory Committee. Minutes of Meeting. Bethesda, MD: National Institutes of Health; March 8, 2001. (On-line) Available: www4.od.nih/oba/RAC/minutes/march82001.pdf
104. Daly T, Lorenz R, Sands MS. Immunologic defect in a murine model of a lysosomal storage disease. Pediatr Res 2000;47:757-762
105. Dong J-Y, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996;7:2101-2112
106. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000;95:1594-1599
107. Gao G-P, Alvira M, Wang L, et al. Novel adeno-associated viruses from Rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002;99: 11854-11859
108. Tsui LV, Kelly M, Zayek N, et al. Production of human clotting factor IX without toxicity in mice after vascular delivery of a lentiviral vector. Nat Biotechnol 2002;20: 53-57
109. Lin Y, Chang L, Solovey A, et al. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 2002;99:457-462
110. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999;104:369-370